Literature DB >> 8032594

Possible role of cyclic AMP phosphodiesterases in the actions of ibudilast on eosinophil thromboxane generation and airways smooth muscle tone.

J E Souness1, M E Villamil, L C Scott, A Tomkinson, M A Giembycz, D Raeburn.   

Abstract

1. The possible role of cyclic AMP phosphodiesterase (PDE) in the inhibitory actions of ibudilast on tracheal smooth muscle contractility and eosinophil thromboxane generation was investigated. 2. Ibudilast was a non-selective inhibitor of partially purified cyclic nucleotide PDE isoenzymes from pig aorta and bovine tracheal smooth muscle, exhibiting only moderate potency against bovine tracheal PDE IV (IC50 = 12 +/- 4 microM, n = 3). Similar or slightly lower potencies were displayed against PDEs I, II, III and V. In contrast, rolipram exhibited selectivity for PDE IV (3 +/- 0.5 microM, n = 3). 3. Ibudilast (IC50 = 0.87 +/- 0.37 microM, n = 3), like rolipram (IC50 = 0.20 +/- 0.04 microM, n = 3), was a more potent inhibitor of membrane-bound PDE IV from guinea-pig eosinophils than of partially purified PDE IV from bovine tracheal smooth muscle. The potency of ibudilast increased when the eosinophil enzyme was solubilised with deoxycholate and NaCl (IC50 = 0.11 +/- 0.05 microM, n = 3) or exposed to vanadate/glutathione complex (V/GSH) (IC50 = 0.11 +/- 0.02 microM, n = 3). The potency of rolipram was also increased by solubilization (IC50 = 0.012 +/- 0.003, n = 3) or V/GSH (IC50 = 0.012 +/- 0.003, n = 3). 4. In intact eosinophils, ibudilast (0.032 microM-20 microM) potentiated isoprenaline-induced cyclic AMP accumulation in a concentration-dependent manner, being approximately 20 fold less potent than rolipram. Little or no effect on basal cyclic AMP levels was observed with either compound. The cyclicAMP-dependent protein kinase activity ratio was significantly increased following incubation of eosinophils with either ibudilast (20 MicroM) or rolipram (20 MicroM) in the absence or presence of isoprenaline.5. Leukotriene B4 (300 nM)-induced thromboxane generation from guinea-pig eosinophils was inhibited by ibudilast (IC50 = 11.3 +/- 3.7 MicroM, n = 5) and rolipram (IC50 = 0.280 +/- 0.067 MicroM, n = 5) in a concentration-dependent manner.6. Ibudilast (10 nM-1 MicroM), whilst generally less potent than rolipram (1 nM- 1 MicroM), produced concentration-dependent relaxation of spasmogen (methacholine, histamine, LTD4)-induced tone in the guinea pig isolated tracheal strip. Ibudilast was less potent in reversing the methacholine (IC50 = 1.95 +/- 0.40 JM,n =6)-induced contraction than those of histamine (IC50 = 0.18 +/- 0.70 MicroM, n =6) or leukotriene D4(LTD4, IC50 = 0.12 +/- 0.05 MicroM, n = 6). Rolipram also exhibited a similar pattern of activity, although the difference in potency against methacholine (IC50 = 0.1 +/- 0.01 MicroM, n = 6) compared with the other two spasmogens, histamine (IC50 = 0.034 +/- 0.017 MicroM, n = 7) and LTD4 (IC50 = 0.026 +/- 0.008 MicroM, n = 7), was not as great.7. These results demonstrate that ibudilast, like rolipram, has several biological actions on the eosinophil and airways smooth muscle which may be attributed to inhibition of cyclic AMP PDE. These actions may account, at least in part, for the recently reported anti-asthma effects of ibudilast.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8032594      PMCID: PMC1910157          DOI: 10.1111/j.1476-5381.1994.tb14855.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  28 in total

Review 1.  Assay of cyclic nucleotide phosphodiesterase and resolution of multiple molecular forms of the enzyme.

Authors:  W J Thompson; W L Terasaki; P M Epstein; S J Strada
Journal:  Adv Cyclic Nucleotide Res       Date:  1979

2.  [Allergen-induced late bronchoconstriction and airway hyperresponsiveness in guinea pigs].

Authors:  H Hoshino; H Kobayashi; S Konno; A Okazawa; Y Okada; T Suganuma; S Maruyama; M Adachi; T Takahashi
Journal:  Arerugi       Date:  1989-04

3.  Bronchodilating effect of KC-404, a novel anti-asthmatic agent, and its derivatives in monkey.

Authors:  S Mue; T Ishihara; W Hida; K Sekizawa; G Tamura; K Yamauchi; H Ohtsu; T Takishima
Journal:  Arch Int Pharmacodyn Ther       Date:  1986-09

4.  The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle. Implications for the mechanism of action of selective phosphodiesterase inhibitors.

Authors:  M L Reeves; B K Leigh; P J England
Journal:  Biochem J       Date:  1987-01-15       Impact factor: 3.857

5.  A new vasodilator 3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine (KC-404) has a dual mechanism of action on platelet aggregation.

Authors:  M Ohashi; H Ohkubo; J Kito; K Nishino
Journal:  Arch Int Pharmacodyn Ther       Date:  1986-10

6.  Inhibition of histamine-stimulated inositol phospholipid hydrolysis by agents which increase cyclic AMP levels in bovine tracheal smooth muscle.

Authors:  I P Hall; J Donaldson; S J Hill
Journal:  Br J Pharmacol       Date:  1989-06       Impact factor: 8.739

7.  Antagonistic effect of KC-404, a new anti-asthmatic agent, on leukotriene D4-induced contractile responses in isolated guinea pig smooth muscles.

Authors:  M Ohashi; R Kanai; K Nishino; T Sato; I Takayanagi
Journal:  Prostaglandins       Date:  1986-12

8.  Pharmacological studies on newly synthesized anti-allergic agents, 2-methyl-3-piperidino-beta-propionaphtone hydrochloride (KZ-111) and 3-isobutyryl-2-isopropylpyrazole-[1, 5-a] pyridine (KC-404).

Authors:  H Nagai; T Iwamoto; T Nishiyori; T Takizawa; H Tsuchiya; A Koda
Journal:  Jpn J Pharmacol       Date:  1983-12

9.  Effects of SK&F 94120, an inhibitor of cyclic nucleotide phosphodiesterase type III, on human platelets.

Authors:  A W Simpson; M L Reeves; T J Rink
Journal:  Biochem Pharmacol       Date:  1988-06-15       Impact factor: 5.858

10.  Adipocyte cyclic nucleotide phosphodiesterase activation by vanadate.

Authors:  J E Souness; W J Thompson; S J Strada
Journal:  J Cyclic Nucleotide Protein Phosphor Res       Date:  1985
View more
  10 in total

1.  Reduction of alcohol drinking of alcohol-preferring (P) and high-alcohol drinking (HAD1) rats by targeting phosphodiesterase-4 (PDE4).

Authors:  Kelle M Franklin; Sheketha R Hauser; Amy W Lasek; Jeanette McClintick; Zheng-Ming Ding; William J McBride; Richard L Bell
Journal:  Psychopharmacology (Berl)       Date:  2015-01-15       Impact factor: 4.530

Review 2.  Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here?

Authors:  M A Giembycz
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

3.  Ibudilast attenuates astrocyte apoptosis via cyclic GMP signalling pathway in an in vitro reperfusion model.

Authors:  K Takuma; E Lee; R Enomoto; K Mori; A Baba; T Matsuda
Journal:  Br J Pharmacol       Date:  2001-07       Impact factor: 8.739

4.  Effects of agents which elevate cyclic AMP on guinea-pig eosinophil homotypic aggregation.

Authors:  M M Teixeira; A G Rossi; M A Giembycz; P G Hellewell
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

Review 5.  Therapeutic Strategies Under Development Targeting Inflammatory Mechanisms in Amyotrophic Lateral Sclerosis.

Authors:  Sebastiano Giuseppe Crisafulli; Simona Brajkovic; Maria Sara Cipolat Mis; Valeria Parente; Stefania Corti
Journal:  Mol Neurobiol       Date:  2017-04-28       Impact factor: 5.590

6.  Suppression of eosinophil function by RP 73401, a potent and selective inhibitor of cyclic AMP-specific phosphodiesterase: comparison with rolipram.

Authors:  J E Souness; C Maslen; S Webber; M Foster; D Raeburn; M N Palfreyman; M J Ashton; J A Karlsson
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

7.  Cyclic AMP-elevating agents prolong or inhibit eosinophil survival depending on prior exposure to GM-CSF.

Authors:  M P Hallsworth; M A Giembycz; P J Barnes; T H Lee
Journal:  Br J Pharmacol       Date:  1996-01       Impact factor: 8.739

8.  Evidence for a role for cyclic AMP in modulating the action of 5-HT and an excitatory neuropeptide, FLP17A, in the pharyngeal muscle of Caenorhabditis elegans.

Authors:  Sylvana Papaioannou; Lindy Holden-Dye; Robert J Walker
Journal:  Invert Neurosci       Date:  2008-05-08

9.  Anti-inflammatory and bronchodilator properties of RP 73401, a novel and selective phosphodiesterase type IV inhibitor.

Authors:  D Raeburn; S L Underwood; S A Lewis; V R Woodman; C H Battram; A Tomkinson; S Sharma; R Jordan; J E Souness; S E Webber
Journal:  Br J Pharmacol       Date:  1994-12       Impact factor: 8.739

10.  A double-blind, randomized, placebo-controlled pilot trial to determine the efficacy and safety of ibudilast, a potential glial attenuator, in chronic migraine.

Authors:  Yuen H Kwok; James E Swift; Parisa Gazerani; Paul Rolan
Journal:  J Pain Res       Date:  2016-10-31       Impact factor: 3.133

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.